Vosoritide Injection

Phase 2

BioMarin Pharmaceutical Inc. (BMRN)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

BMRNPhase 2$10.6B

Vosoritide Injection Phase 2 Est. Readout

Vosoritide Injection• Short Stature Homeobox- Containing Gene SHOX Deficiency30

Mar 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Short Stature Homeobox- Containing Gene SHOX Deficiency

View Full Landscape

Drug Information

Target Indication

Short Stature Homeobox- Containing Gene SHOX Deficiency

Clinical Trial

NCT06668805

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BMRN

BioMarin Pharmaceutical Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

BMN 165Phase 3

Phenylketonuria

Valoctocogene roxaparvovecPhase 3

Hemophilia A With Inhibitor

BMN 110 - WeeklyPhase 3

Mucopolysaccharidosis IV A

sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterinPhase 3

Phenylketonurias

Kuvan®Phase 3

Phenylketonuria

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts